Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

AIDS research and human retroviruses - 1 Sept 1999

Churchill D R, Pym A S, Galpin S, Foxall R, Stainsby C, Clarke J R, Kaye S, Bloor S, Larder B A, Wills B, Sun E, Babiker A G, Back D J, Weber J N

Abstract excerpt

Thirteen protease inhibitor-naive patients with HIV-1 infection, and 12 patients with a median of 58 months prior treatment with saquinavir (SQV) monotherapy, were treated with SQV (400 mg twice daily) and ritonavir (RIT, 500 mg twice daily) in a study designed to assess the effect of prior treatment with SQV monotherapy on the antiretroviral activity of RIT-SQV combination therapy. Median baseline viral load and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Drug Resistance, Microbial

Share to Gene Products, pol

Share to HIV Protease Inhibitors

Share to Ritonavir

Share to Saquinavir

Source

Identifiers

PMID: 10480631
DOI: 10.1089/088922299310278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.PMID 10480631Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.Semantic proximity Read ↗

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.Semantic proximity Read ↗

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.Semantic proximity Read ↗

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.Semantic proximity Read ↗

The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.Semantic proximity Read ↗

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.Semantic proximity Read ↗

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Protease inhibitors: drug resistance and cross resistance overview.Semantic proximity Read ↗

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.